Why the study?
Cardiac adverse events are common with tyrosine kinase inhibitors, prompting exploration of their cardiac toxicities using the FAERS database.
What are the specific cardiac adverse events associated with different tyrosine kinase inhibitors in patients with hepatocellular cancer?
Population
4708 cardiac adverse event reports of sorafenib, regorafenib, lenvatinib, and cabozantinib in FAERS
Comparison
Sorafenib vs regorafenib vs lenvatinib vs cabozantinib
Design
Retrospective pharmacovigilance study using disproportionality and Bayesian analysis
Key result
Lenvatinib exposure was associated with a strong signal for cardiac failure (ROR 7.7; 95% CI 3.46-17.17) and acute coronary syndrome, while sorafenib was linked to aortic dissections.
Authors
Loading...
Cardiac AE signals with these TKIs merit clinical awareness; hypothesis-generating and leaves open need for prospective validation.
Observational (n=4,708)
What are the specific cardiac adverse events associated with different tyrosine kinase inhibitors in patients with hepatocellular cancer?
Odds Ratio: 7.7 (95% CI 3.46–17.17)
Different tyrosine kinase inhibitors used for hepatocellular cancer have distinct profiles of cardiac toxicities, with lenvatinib showing strong signals for heart failure and acute coronary syndrome, highlighting the need for tailored cardiovascular monitoring.
Lai et al. (2023) conducted an observational in Hepatocellular cancer (n=4,708). Tyrosine kinase inhibitors (sorafenib, regorafenib, lenvatinib, cabozantinib) was evaluated on Cardiac adverse events (ROR 7.7, 95% CI 3.46-17.17). Lenvatinib exposure was associated with a strong signal for cardiac failure (ROR 7.7; 95% CI 3.46-17.17) and acute coronary syndrome, while sorafenib was linked to aortic dissections.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: